News
Update
2024-09-30
GenEditBio Secures Strategic Investment from Gobi Partners GBA to Accelerate Breakthrough Genome Editing Technologies
Mission
Build precision gene editing technology platform and develop a clinical pipeline of programmable gene therapy products that are safe and effective.
Platform
GenEditBio has multiple technology platforms to tackle bottlenecks restricting in vivo gene editing therapy.
Pipeline
GenEditBio are working with efficient, versatile and safe gene editing tools which have distinct gene editing and targeting capabilities. Using these tools, we can access a broad range of genetic mutations and develop targeted and durable in vivo gene edited medicines.
We use Cookies to give you a better experience on our website. By continuing to browse the site without changing your privacy settings, you are consenting to our use of Cookies. For more information, please see our Privacy Policy Statement.
Copyright@GenEditBio.Beijing 丨 京ICP备2022025189号